CLAIMS

1. A pharmaceutical composition in the form of a soft capsule for oral administration comprising:
   a. 1 to 35% (w/w) of fexofenadine hydrochloride ;
   b. At least 60%(w/w) of a liquid mixture of at least one non-ionic hydrophilic surfactant and at least one non-ionic hydrophobic surfactant.

2. The pharmaceutical composition according to claim 1, wherein the fexofenadine hydrochloride has a specific surface area ranging from 1.0 and 4.0 m^2/g.

3. The pharmaceutical composition according to claim 1, wherein the total amount of surfactant is ranging from 65 to 85% by weight of the composition.

4. The pharmaceutical composition according to claim 1, wherein the non-ionic hydrophobic surfactant has an HLB value from 4 to 6.

5. The pharmaceutical composition according to claim 1, wherein the non-ionic hydrophobic surfactant is chosen from the group consisting of propylene glycol laurate, propylene glycol monocaprylate and mixture thereof.

6. The pharmaceutical composition according to claim 1, wherein the hydrophobic surfactant is present in amounts ranging from 75% to 80% by weight of the composition.

7. The pharmaceutical composition according to claim 1, wherein the non-ionic hydrophilic surfactant has an HLB value from 11 to 16.

8. The pharmaceutical composition according to claim 1, wherein the non-ionic hydrophilic surfactant is the polysorbate 80.

9. The pharmaceutical composition according to claim 1, wherein the non-ionic hydrophilic surfactant is present in amounts ranging from 1% to 10% by weight of the composition.

10. The pharmaceutical composition according to claim 1, wherein the weight ratio of fexofenadine hydrochloride to the total liquid mixture of surfactant is 1:4.

11. The pharmaceutical composition according to claim 1, wherein the non-ionic hydrophobic surfactant is propylene glycol monolaurate and the non-ionic hydrophilic surfactant is polysorbate 80.

~~12. The pharmaceutical composition according to any one of the claims 1 to 11, wherein the final pH value of the composition is between 4 and 9.~~

~~13. The pharmaceutical composition according to any one of the claims 1 to 12, in the form of a soft capsule.~~

~~14~~12. A method for preparing a pharmaceutical preparation according to any one of claims 1 to ~~13~~ 11, comprising the following successive steps: dissolving the fexofenadine hydrochloride in a liquid mixture of at least one non-ionic hydrophilic surfactant and at least one non-ionic hydrophobic surfactant, with stirring, in order to obtain an homogeneous mixture; and then adjust the pH between 5-6 using suficient quantity of an acidifying or a basifying agent.

~~15~~13. The use of a composition as claimed in any one of claims 1 to ~~13~~11, for the preparation of a drug for the treatment of allergic reactions in a patient.